RepTB: a gene ontology based drug repurposing approach for tuberculosis

Manjelievskaia J, Erck D, Piracha S, Schrager L (2016) Drug-resistant TB: deadly, costly and in need of a vaccine. Trans R Soc Trop Med Hyg 110(3):186–191 WHO (2016) Global tuberculosis report 2016. World Health Organization, Geneva Kendall EA, Fojo AT, Dowdy DW (2016) Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis. Lancet Respir Med 5(3):191–199 Ramappa V, Aithal GP (2013) Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. J Clin Exp Hepatol. 3(1):37–49 Beebe A, Seaworth B, Patil N (2015) Rifampicin-induced nephrotoxicity in a tuberculosis patient. J Clin Tuberc Other Mycobact Dis 1:13–15 Berkrot B (2011) Success rates for experimental drugs falls: study. Thomson Reuters, Toronto Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 6(1):29–40 Thomson R (2012) knowledge-based drug repositioningto drive R&D productivity. Thompson Reuters, Toronto Kerber R (2003) Old drugs, new life. The Boston Globe, Boston Konemann S, Dorr M, Felix SB (2017) Cardiac immunomodulation. In: Nusinovitch U (ed) The heart in rheumatic, autoimmune and inflammatory diseases. pp 681–714 Palomino JC, Martin A (2013) Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J Antimicrob Chemother 68(2):275–283 Zumla A, Nahid P, Cole ST (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12(5):388–404 Carroll MW, Jeon D, Mountz JM, Lee JD, Jeong YJ, Zia N et al (2013) Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother 57(8):3903–3909 Ramón-García S, González del Río R, Villarejo AS, Sweet GD, Cunningham F, Barros D et al (2016) Repurposing clinically approved cephalosporins for tuberculosis therapy. 6:34293 Leegwater-Kim J, Waters C (2007) Role of tolcapone in the treatment of Parkinson’s disease. Expert Rev Neurother 7(12):1649–1657 Maitra A, Bates S, Shaik M, Evangelopoulos D, Abubakar I, McHugh TD et al (2016) Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs. Br Med Bull 118(1):138–148 Lechartier B, Rybniker J, Zumla A, Cole ST (2014) Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med 6(2):158–168 Brindha S, Sundaramurthi JC, Velmurugan D, Vincent S, Gnanadoss JJ (2016) Docking-based virtual screening of known drugs against murE of Mycobacterium tuberculosis towards repurposing for TB. Bioinformation 12(8):359–367 Brindha S, Vincent S, Velmurugan D, Ananthakrishnan D, Sundaramurthi JC, Gnanadoss JJ (2017) Bioinformatics approach to prioritize known drugs towards repurposing for tuberculosis. Med Hypotheses 103:39–45 Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, Bourne PE (2010) The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol 6(11):e1000976 Ramakrishnan G, Chandra NR, Srinivasan N (2015) Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv. Mol BioSyst 11(12):3316–3331 Yamanishi Y, Kotera M, Kanehisa M, Goto S (2010) Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 26(12):i246–i254 Seal A, Ahn YY, Wild DJ (2015) Optimizing drug-target interaction prediction based on random walk on heterogeneous networks. J Cheminform 7:40 Isik Z, Baldow C, Cannistraci CV, Schroeder M (2015) Drug target prioritization by perturbed gene expression and network information. Sci Rep 5:17417 Cheng F, Liu C, Jiang J, Lu W, Li W, Liu G et al (2012) Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 8(5):e1002503 Zhou T, Ren J, Medo M, Zhang YC (2007) Bipartite network projection and personal recommendation. Phys Rev E: Stat, Nonlin, Soft Matter Phys 76(4 Pt 2):046115 Guo ZR (2011) Drug promiscuity. Yao Xue Xue Bao 46(4):361–369 Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y et al (2014) DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res 42(D1):Database issue–Database issue1097 Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A et al (2011) DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res 39(Database issue):D1035–D1041 Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D et al (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36(D1):D901–D906 Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P et al (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34(Database issue):D668–D672 Huntley RP, Sawford T, Mutowo-Meullenet P, Shypitsyna A, Bonilla C, Martin MJ et al (2015) The GOA database: gene ontology annotation updates for 2015. Nucleic Acids Res 43(D1):D1057–D1063 Binns D, Dimmer E, Huntley R, Barrell D, O’Donovan C, Apweiler R (2009) QuickGO: a web-based tool for gene ontology searching. Bioinformatics 25(22):3045–3046 Chan S, Segelke B, Lekin T, Krupka H, Cho US, Kim MY et al (2004) Crystal structure of the Mycobacterium tuberculosis dUTPase: insights into the catalytic mechanism. J Mol Biol 341(2):503–517 Carroll P, Faray-Kele MC, Parish T (2011) Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. Appl Environ Microbiol 77(14):5040–5043 Bermingham A, Derrick JP (2002) The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. BioEssays 24(7):637–648 Baca AM, Sirawaraporn R, Turley S, Sirawaraporn W, Hol WG (2000) Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: new insight into the enzymatic mechanism and sulfa-drug action. J Mol Biol 302(5):1193–1212 Liu T, Wang B, Guo J, Zhou Y, Julius M, Njire M et al (2015) Role of folP1 and folP2 genes in the action of sulfamethoxazole and trimethoprim against mycobacteria. J Microbiol Biotechnol 25(9):1559–1567 Skold O (2000) Sulfonamide resistance: mechanisms and trends. Drug Resist Updat 3(3):155–160 Hammoudeh DI, Zhao Y, White SW, Lee RE (2013) Replacing sulfa drugs with novel DHPS inhibitors. Future Med Chem 5(11):1331–1340 Hevener KE, Yun MK, Qi J, Kerr ID, Babaoglu K, Hurdle JG et al (2010) Structural studies of pterin-based inhibitors of dihydropteroate synthase. J Med Chem 53(1):166–177 Zhao Y, Hammoudeh D, Yun MK, Qi J, White SW, Lee RE (2012) Structure-based design of novel pyrimido[4,5-c]pyridazine derivatives as dihydropteroate synthase inhibitors with increased affinity. ChemMedChem 7(5):861–870 Villela AD, Sanchez-Quitian ZA, Ducati RG, Santos DS, Basso LA (2011) Pyrimidine salvage pathway in Mycobacterium tuberculosis. Curr Med Chem 18(9):1286–1298 Vanheusden V, Van Rompaey P, Munier-Lehmann H, Pochet S, Herdewijn P, Van Calenbergh S (2003) Thymidine and thymidine-5′-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. Bioorg Med Chem Lett 13(18):3045–3048 Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48(1):77–84 Vertessy BG, Toth J (2009) Keeping uracil out of DNA: physiological role, structure and catalytic mechanism of dUTPases. Acc Chem Res 42(1):97–106 El-Hajj HH, Zhang H, Weiss B (1988) Lethality of a dut (deoxyuridine triphosphatase) mutation in Escherichia coli. J Bacteriol. 170(3):1069–1075 Gadsden MH, McIntosh EM, Game JC, Wilson PJ, Haynes RH (1993) dUTP pyrophosphatase is an essential enzyme in Saccharomyces cerevisiae. EMBO J 12(11):4425–4431 Kaur P, Agarwal S, Datta S (2009) Delineating bacteriostatic and bactericidal targets in mycobacteria using IPTG inducible antisense expression. PLoS ONE 4(6):e5923 Ramachandran V, Singh R, Yang X, Tunduguru R, Mohapatra S, Khandelwal S et al (2013) Genetic and chemical knockdown: a complementary strategy for evaluating an anti-infective target. Adv Appl Bioinform Chem 6:1–13 Black PA, Warren RM, Louw GE, van Helden PD, Victor TC, Kana BD (2014) Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58(5):2491–2503 Dhiman RK, Mahapatra S, Slayden RA, Boyne ME, Lenaerts A, Hinshaw JC et al (2009) Menaquinone synthesis is critical for maintaining mycobacterial viability during exponential growth and recovery from non-replicating persistence. Mol Microbiol 72(1):85–97 Braback M, Riesbeck K, Forsgren A (2002) Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Antimicrob Agents Chemother 46(4):1114–1116 Eliopoulos GM, Wennersten CB (2002) Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother 46(5):1319–1324 Evans JC, Trujillo C, Wang Z, Eoh H, Ehrt S, Schnappinger D et al (2016) Validation of CoaBC as a bactericidal target in the coenzyme a pathway of Mycobacterium tuberculosis. ACS Infect Dis. 2(12):958–968 Manjunatha UH, Rao SPS, Kondreddi RR, Noble CG, Camacho LR, Tan BH et al (2015) Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci Transl Med. 7(269):269r3 Alland C, Moreews F, Boens D, Carpentier M, Chiusa S, Lonquety M et al (2005) RPBS: a web resource for structural bioinformatics. Nucleic Acids Res. 33(W1):W44–W49 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504